HRP20100408T1 - DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI - Google Patents

DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI Download PDF

Info

Publication number: HRP20100408T1
Authority: HR; Croatia
Prior art keywords: cycloalkyl; alkyl; phenyl; pyridin; imidazo
Prior art date: 2006-09-22

Application number

HR20100408T

Other languages

English (en)

Croatian (hr)

Inventor

Antonio Almario Garcia

Lardenois Patrick

Olivier Anne

Original Assignee

Sanofi-Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-22

Filing date

2010-07-23

Publication date

2010-09-30

2010-07-23 Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis

2010-09-30 Publication of HRP20100408T1 publication Critical patent/HRP20100408T1/hr

Links

238000002360 preparation method Methods 0.000 title claims 9
230000001225 therapeutic effect Effects 0.000 title 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 85
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 72
229910052736 halogen Inorganic materials 0.000 claims abstract 55
125000003118 aryl group Chemical group 0.000 claims abstract 47
150000002367 halogens Chemical class 0.000 claims abstract 44
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 42
150000001875 compounds Chemical class 0.000 claims abstract 35
125000002947 alkylene group Chemical group 0.000 claims abstract 33
229910003827 NRaRb Inorganic materials 0.000 claims abstract 25
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 24
125000004093 cyano group Chemical group *C#N 0.000 claims abstract 23
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 20
125000001424 substituent group Chemical group 0.000 claims abstract 17
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 16
125000000753 cycloalkyl group Chemical group 0.000 claims abstract 14
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract 12
125000004429 atom Chemical group 0.000 claims abstract 10
125000005529 alkyleneoxy group Chemical group 0.000 claims abstract 8
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 6
125000001624 naphthyl group Chemical group 0.000 claims abstract 5
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims abstract 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims abstract 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract 4
125000000000 cycloalkoxy group Chemical group 0.000 claims abstract 4
125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims abstract 2
XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims abstract 2
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims abstract 2
229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
125000004001 thioalkyl group Chemical group 0.000 claims abstract 2
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims abstract 2
125000005843 halogen group Chemical group 0.000 claims 13
150000003839 salts Chemical class 0.000 claims 11
239000002253 acid Substances 0.000 claims 10
229940079593 drug Drugs 0.000 claims 8
239000003814 drug Substances 0.000 claims 8
230000002265 prevention Effects 0.000 claims 7
-1 (C3-C7)CycloAlkoxy Chemical group 0.000 claims 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
125000006557 (C2-C5) alkylene group Chemical group 0.000 claims 2
MYONEJYVJVQVAF-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 MYONEJYVJVQVAF-UHFFFAOYSA-N 0.000 claims 2
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 2
238000006482 condensation reaction Methods 0.000 claims 2
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
238000000034 method Methods 0.000 claims 2
238000002054 transplantation Methods 0.000 claims 2
PDCSZSDAIIGGJS-UHFFFAOYSA-N 1-[3-[2-(2,4-difluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C(=CC(F)=CC=2)F)=C1 PDCSZSDAIIGGJS-UHFFFAOYSA-N 0.000 claims 1
YSCIMARAKJTOQO-UHFFFAOYSA-N 1-[3-[2-(2-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C(=CC=CC=2)Cl)=C1 YSCIMARAKJTOQO-UHFFFAOYSA-N 0.000 claims 1
VAQRCUNRDMEKOK-UHFFFAOYSA-N 1-[3-[2-(3,4-difluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=C(F)C(F)=CC=2)=C1 VAQRCUNRDMEKOK-UHFFFAOYSA-N 0.000 claims 1
ZSUXFNRFDYZPEB-UHFFFAOYSA-N 1-[3-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol 4-[6-[3-(hydroxymethyl)phenyl]imidazo[1,2-a]pyridin-2-yl]phenol Chemical compound OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC=C(C=C2)O.ClC=2C=C(C=CC2)C=2N=C1N(C=C(C=C1)C=1C=C(C=CC1)C(C)O)C2 ZSUXFNRFDYZPEB-UHFFFAOYSA-N 0.000 claims 1
SOLQRLFTNWMKLR-UHFFFAOYSA-N 1-[3-[2-(3-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=C(F)C=CC=2)=C1 SOLQRLFTNWMKLR-UHFFFAOYSA-N 0.000 claims 1
UBTSBKDDTUQXRU-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]-3-methylbutan-1-ol Chemical compound CC(C)CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 UBTSBKDDTUQXRU-UHFFFAOYSA-N 0.000 claims 1
JZTXDXUREYZCFA-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]heptan-1-ol Chemical compound CCCCCCC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 JZTXDXUREYZCFA-UHFFFAOYSA-N 0.000 claims 1
LGZVZMDOBADMFD-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]pentan-1-ol Chemical compound CCCCC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 LGZVZMDOBADMFD-UHFFFAOYSA-N 0.000 claims 1
PCLPUMSFIGAPDD-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]propan-1-ol Chemical compound CCC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 PCLPUMSFIGAPDD-UHFFFAOYSA-N 0.000 claims 1
JTTPDWXPTGRTJI-UHFFFAOYSA-N 1-[3-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(F)=CC=2)=C1 JTTPDWXPTGRTJI-UHFFFAOYSA-N 0.000 claims 1
NFXJURRZLLYBPN-UHFFFAOYSA-N 1-[4-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound C1=CC(C(O)C)=CC=C1C1=CN2C=C(C=3C=CC(Cl)=CC=3)N=C2C=C1 NFXJURRZLLYBPN-UHFFFAOYSA-N 0.000 claims 1
ZYANTTOKFDWNGJ-UHFFFAOYSA-N 1-[4-[[3-[2-(4-methylphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]methoxy]phenyl]ethanone 2-(4-methylphenyl)-6-[3-[[4-(trifluoromethyl)phenoxy]methyl]phenyl]imidazo[1,2-a]pyridine Chemical compound FC(C1=CC=C(OCC=2C=C(C=CC2)C=2C=CC=3N(C2)C=C(N3)C3=CC=C(C=C3)C)C=C1)(F)F.C1(=CC=C(C=C1)C=1N=C3N(C=C(C=C3)C=3C=C(COC2=CC=C(C=C2)C(C)=O)C=CC3)C1)C ZYANTTOKFDWNGJ-UHFFFAOYSA-N 0.000 claims 1
HYURVCUMJWEFMW-UHFFFAOYSA-N 2-(4-chlorophenyl)-6-[2-(methoxymethyl)phenyl]imidazo[1,2-a]pyridine;hydrochloride Chemical compound Cl.COCC1=CC=CC=C1C1=CN2C=C(C=3C=CC(Cl)=CC=3)N=C2C=C1 HYURVCUMJWEFMW-UHFFFAOYSA-N 0.000 claims 1
OBWVJVVNWMBROP-UHFFFAOYSA-N 2-(4-chlorophenyl)-6-[4-(methoxymethyl)phenyl]imidazo[1,2-a]pyridine Chemical compound C1=CC(COC)=CC=C1C1=CN2C=C(C=3C=CC(Cl)=CC=3)N=C2C=C1 OBWVJVVNWMBROP-UHFFFAOYSA-N 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
QLTFWCTVWLJGQX-UHFFFAOYSA-N C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(COC3=CC=C(C#N)C=C3)C=CC2)C1)C.CC1=CC=C(OCC=2C=C(C=CC2)C=2C=CC=3N(C2)C=C(N3)C3=CC=C(C=C3)C)C=C1.[N+](=O)([O-])C=1C=C(OCC=3C=C(C=CC3)C=3C=CC=2N(C3)C=C(N2)C2=CC=C(C=C2)C)C=CC1 Chemical compound C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(COC3=CC=C(C#N)C=C3)C=CC2)C1)C.CC1=CC=C(OCC=2C=C(C=CC2)C=2C=CC=3N(C2)C=C(N3)C3=CC=C(C=C3)C)C=C1.[N+](=O)([O-])C=1C=C(OCC=3C=C(C=CC3)C=3C=CC=2N(C3)C=C(N2)C2=CC=C(C=C2)C)C=CC1 QLTFWCTVWLJGQX-UHFFFAOYSA-N 0.000 claims 1
VZMAEKSHJBIDKO-UHFFFAOYSA-N C1(=CC=CC2=CC=CC=C12)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C(C)N(C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1)CC Chemical compound C1(=CC=CC2=CC=CC=C12)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C(C)N(C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1)CC VZMAEKSHJBIDKO-UHFFFAOYSA-N 0.000 claims 1
QUXHWCXYIKKQDS-UHFFFAOYSA-N COC1=C(C=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound COC1=C(C=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 QUXHWCXYIKKQDS-UHFFFAOYSA-N 0.000 claims 1
QZZBPRCKWNYDOY-UHFFFAOYSA-N COCCOCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC1=CC=CC=C1C=C2.CC2=C(C=CC(=C2)C)C=2N=C1N(C=C(C=C1)C=1C=C(C=CC1)CO)C2 Chemical compound COCCOCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC1=CC=CC=C1C=C2.CC2=C(C=CC(=C2)C)C=2N=C1N(C=C(C=C1)C=1C=C(C=CC1)CO)C2 QZZBPRCKWNYDOY-UHFFFAOYSA-N 0.000 claims 1
PRSURGCTCWKNQS-UHFFFAOYSA-N Cc1ccc(cc1)-c1cn2cc(ccc2n1)-c1cccc(COc2ccc(Cl)cc2)c1.CC(=O)Nc1ccc(OCc2cccc(c2)-c2ccc3nc(cn3c2)-c2ccc(C)cc2)cc1 Chemical compound Cc1ccc(cc1)-c1cn2cc(ccc2n1)-c1cccc(COc2ccc(Cl)cc2)c1.CC(=O)Nc1ccc(OCc2cccc(c2)-c2ccc3nc(cn3c2)-c2ccc(C)cc2)cc1 PRSURGCTCWKNQS-UHFFFAOYSA-N 0.000 claims 1
STGKULPTJBQCKB-UHFFFAOYSA-N Cl.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)CO)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)CO)C1 Chemical compound Cl.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)CO)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)CO)C1 STGKULPTJBQCKB-UHFFFAOYSA-N 0.000 claims 1
CHLWMYLAYHUWKV-UHFFFAOYSA-N Cl.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound Cl.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 CHLWMYLAYHUWKV-UHFFFAOYSA-N 0.000 claims 1
XISBGQXCHIJQBU-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)C.ClC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound ClC1=C(C=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)C.ClC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 XISBGQXCHIJQBU-UHFFFAOYSA-N 0.000 claims 1
DCDKUYUYSWGOPX-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)COC)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)C(C)O)C1 Chemical compound ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)COC)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)C(C)O)C1 DCDKUYUYSWGOPX-UHFFFAOYSA-N 0.000 claims 1
YBHUYJLFUBUVPZ-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)COC)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)C(C)O)C1 Chemical compound ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)COC)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)C(C)O)C1 YBHUYJLFUBUVPZ-UHFFFAOYSA-N 0.000 claims 1
NHPDCHQXQGOMHW-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)C(C)(C)O)C1.FC=1C=C(C=CC1C)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)C(C)(C)O)C1.FC=1C=C(C=CC1C)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 NHPDCHQXQGOMHW-UHFFFAOYSA-N 0.000 claims 1
VRGLPXBXHOEQCL-UHFFFAOYSA-N FC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC1=C(C=CC(=C1)OC)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound FC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC1=C(C=CC(=C1)OC)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 VRGLPXBXHOEQCL-UHFFFAOYSA-N 0.000 claims 1
CJPPQXQVGDELPM-UHFFFAOYSA-N FC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.ClC=1C=C(C=CC1Cl)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound FC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.ClC=1C=C(C=CC1Cl)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 CJPPQXQVGDELPM-UHFFFAOYSA-N 0.000 claims 1
MPXXJIXCNWQVSU-UHFFFAOYSA-N FC=1C=C(C=CC1F)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.FC1=C(C=CC(=C1)F)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound FC=1C=C(C=CC1F)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.FC1=C(C=CC(=C1)F)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 MPXXJIXCNWQVSU-UHFFFAOYSA-N 0.000 claims 1
UKXGHSHFJVVZHD-UHFFFAOYSA-N N1(CCCC1)C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1.C1(=CC=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C1(=CC=CC=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1 Chemical compound N1(CCCC1)C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1.C1(=CC=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C1(=CC=CC=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1 UKXGHSHFJVVZHD-UHFFFAOYSA-N 0.000 claims 1
RJMBORZGZOBATF-UHFFFAOYSA-N N1(CCCC1)C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)C.C1=C(C=CC2=CC=CC=C12)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound N1(CCCC1)C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)C.C1=C(C=CC2=CC=CC=C12)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 RJMBORZGZOBATF-UHFFFAOYSA-N 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
DLOYTHNNVWMZAD-UHFFFAOYSA-N OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC=C(C#N)C=C2.COCCOCC=2C=C(C=CC2)C=2C=CC=1N(C2)C=C(N1)C=1C=C(C#N)C=CC1 Chemical compound OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC=C(C#N)C=C2.COCCOCC=2C=C(C=CC2)C=2C=CC=1N(C2)C=C(N1)C=1C=C(C#N)C=CC1 DLOYTHNNVWMZAD-UHFFFAOYSA-N 0.000 claims 1
OKOGJTHOFMPIHZ-UHFFFAOYSA-N OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C=2C=C(C#N)C=CC2.OCC2=CC=C(C=C2)C=2C=CC=1N(C2)C=C(N1)C=1C=C(C#N)C=CC1.C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1)C1=CC=CC=C1 Chemical compound OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C=2C=C(C#N)C=CC2.OCC2=CC=C(C=C2)C=2C=CC=1N(C2)C=C(N1)C=1C=C(C#N)C=CC1.C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1)C1=CC=CC=C1 OKOGJTHOFMPIHZ-UHFFFAOYSA-N 0.000 claims 1
208000001132 Osteoporosis Diseases 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
208000034799 Tauopathies Diseases 0.000 claims 1
HOTODYIWLPMBRK-UHFFFAOYSA-N [3-[2-(2-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]methanol [3-[2-[4-(trifluoromethyl)phenyl]imidazo[1,2-a]pyridin-6-yl]phenyl]methanol Chemical compound FC(C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)(F)F.ClC1=C(C=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 HOTODYIWLPMBRK-UHFFFAOYSA-N 0.000 claims 1
XVDHAJOPZBKJTP-UHFFFAOYSA-N [3-[2-(3,4-difluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]methanol;hydrochloride Chemical compound Cl.OCC1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=C(F)C(F)=CC=2)=C1 XVDHAJOPZBKJTP-UHFFFAOYSA-N 0.000 claims 1
LJPGFWXYBPREBX-UHFFFAOYSA-N [3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]-cyclopentylmethanol Chemical compound C=1C=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=CC=1C(O)C1CCCC1 LJPGFWXYBPREBX-UHFFFAOYSA-N 0.000 claims 1
FLRVREFLPLXHCL-UHFFFAOYSA-N [3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]-phenylmethanol Chemical compound C=1C=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=CC=1C(O)C1=CC=CC=C1 FLRVREFLPLXHCL-UHFFFAOYSA-N 0.000 claims 1
FMDRXVFYGAJKFK-UHFFFAOYSA-N [3-[2-[4-(difluoromethyl)phenyl]imidazo[1,2-a]pyridin-6-yl]phenyl]methanol Chemical compound OCC1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(=CC=2)C(F)F)=C1 FMDRXVFYGAJKFK-UHFFFAOYSA-N 0.000 claims 1
DKKXSGSGLOGHSR-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.FC(OC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)(F)F Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.FC(OC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)(F)F DKKXSGSGLOGHSR-UHFFFAOYSA-N 0.000 claims 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
229910052796 boron Inorganic materials 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
230000002490 cerebral effect Effects 0.000 claims 1
206010015037 epilepsy Diseases 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 claims 1
208000014674 injury Diseases 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
229910052987 metal hydride Inorganic materials 0.000 claims 1
150000004681 metal hydrides Chemical class 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
230000004770 neurodegeneration Effects 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
125000002524 organometallic group Chemical group 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
208000020016 psychiatric disease Diseases 0.000 claims 1
201000000980 schizophrenia Diseases 0.000 claims 1
210000000130 stem cell Anatomy 0.000 claims 1
208000011117 substance-related disease Diseases 0.000 claims 1
230000008733 trauma Effects 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Addiction (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HR20100408T 2006-09-22 2010-07-23 DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI HRP20100408T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0608350A FR2906250B1 (fr)	2006-09-22	2006-09-22	Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
PCT/FR2007/001517 WO2008034974A1 (fr)	2006-09-22	2007-09-19	DERIVES DE 2-ARYL-6-PHENYL-IMIDAZO[1,2-α]PYRIDINES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (1)

Publication Number	Publication Date
HRP20100408T1 true HRP20100408T1 (hr)	2010-09-30

Family

ID=37841968

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100408T HRP20100408T1 (hr)	2006-09-22	2010-07-23	DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI

Country Status (44)

Country	Link
US (1)	US7915284B2 (es)
EP (1)	EP2069342B1 (es)
JP (1)	JP5336378B2 (es)
KR (1)	KR101470039B1 (es)
CN (1)	CN101516881B (es)
AR (1)	AR062897A1 (es)
AT (1)	ATE467633T1 (es)
AU (1)	AU2007298856B2 (es)
BR (1)	BRPI0718517A2 (es)
CA (1)	CA2662848C (es)
CL (1)	CL2007002733A1 (es)
CO (1)	CO6160308A2 (es)
CR (1)	CR10643A (es)
CY (1)	CY1110232T1 (es)
DE (1)	DE602007006525D1 (es)
DK (1)	DK2069342T3 (es)
EA (1)	EA017442B1 (es)
ES (1)	ES2345016T3 (es)
FR (1)	FR2906250B1 (es)
GT (1)	GT200900049A (es)
HK (1)	HK1135388A1 (es)
HN (1)	HN2009000502A (es)
HR (1)	HRP20100408T1 (es)
IL (1)	IL197352A (es)
JO (1)	JO2643B1 (es)
MA (1)	MA30792B1 (es)
ME (1)	ME00615B (es)
MX (1)	MX2009002802A (es)
MY (1)	MY145603A (es)
NI (1)	NI200900037A (es)
NO (1)	NO20091562L (es)
NZ (1)	NZ575337A (es)
PE (1)	PE20080671A1 (es)
PL (1)	PL2069342T3 (es)
PT (1)	PT2069342E (es)
RS (1)	RS51412B (es)
SI (1)	SI2069342T1 (es)
SV (1)	SV2009003193A (es)
TN (1)	TN2009000081A1 (es)
TW (1)	TWI381837B (es)
UA (1)	UA95976C2 (es)
UY (1)	UY30603A1 (es)
WO (1)	WO2008034974A1 (es)
ZA (1)	ZA200901551B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2928923B1 (fr) *	2008-03-21	2010-04-23	Sanofi Aventis	Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2928921B1 (fr) *	2008-03-21	2010-04-23	Sanofi Aventis	Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928924B1 (fr) *	2008-03-21	2010-04-23	Sanofi Aventis	Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928922B1 (fr) *	2008-03-21	2010-04-23	Sanofi Aventis	Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2933609B1 (fr) *	2008-07-10	2010-08-27	Fournier Lab Sa	Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
FR2950345B1 (fr) *	2009-09-18	2011-09-23	Sanofi Aventis	Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
FR2950344B1 (fr) *	2009-09-18	2011-11-25	Sanofi Aventis	Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
FR2953520B1 (fr) *	2009-12-04	2011-11-25	Sanofi Aventis	Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
EP2925756B1 (en) *	2012-11-29	2017-02-01	F. Hoffmann-La Roche AG	Imidazopyridine derivatives
ES2716762T3 (es) *	2013-02-04	2019-06-14	Janssen Pharmaceutica Nv	Moduladores de FLAP
TWI644899B (zh)	2013-02-04	2018-12-21	健生藥品公司	Ｆｌａｐ調節劑
US20160185774A1 (en) *	2013-08-02	2016-06-30	Institut Pasteur Korea	Anti-Infective Compounds
KR20170137165A (ko)	2015-04-10	2017-12-12	베이진 엘티디	인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘
MA52119A (fr)	2015-10-19	2018-08-29	Ncyte Corp	Composés hétérocycliques utilisés comme immunomodulateurs
US20170145025A1 (en)	2015-11-19	2017-05-25	Incyte Corporation	Heterocyclic compounds as immunomodulators
UA126113C2 (uk)	2015-12-22	2022-08-17	Інсайт Корпорейшн	Гетероциклічні сполуки як імуномодулятори
MA44860A (fr)	2016-05-06	2019-03-13	Incyte Holdings Corp	Composés hétérocycliques utilisés comme immunomodulateurs
MA45116A (fr)	2016-05-26	2021-06-02	Incyte Corp	Composés hétérocycliques comme immunomodulateurs
CA3028685A1 (en)	2016-06-20	2017-12-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
MA45669A (fr)	2016-07-14	2019-05-22	Incyte Corp	Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en)	2016-08-29	2018-03-01	Incyte Corporation	Heterocyclic compounds as immunomodulators
US10882856B2 (en)	2016-09-24	2021-01-05	Beigene, Ltd.	5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
ES2899402T3 (es)	2016-12-22	2022-03-11	Incyte Corp	Derivados de piridina como inmunomoduladores
HUE060233T2 (hu)	2016-12-22	2023-02-28	Incyte Corp	Tetrahidro imidazo[4,5-c]piridin-származékok mint a PD-L1 internalizációját indukáló szerek
US20180179201A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2018119266A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Benzooxazole derivatives as immunomodulators
WO2019101188A1 (en)	2017-11-25	2019-05-31	Beigene, Ltd.	Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases
IL313101A (en)	2018-03-30	2024-07-01	Incyte Corp	Heterocyclic compounds as immunomodulators
TWI821288B (zh)	2018-05-11	2023-11-11	美商英塞特公司	作為免疫調節劑之雜環化合物
EP4010342A1 (en)	2019-08-09	2022-06-15	Incyte Corporation	Salts of a pd-1/pd-l1 inhibitor
AR120109A1 (es)	2019-09-30	2022-02-02	Incyte Corp	Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
CN114829366A (zh)	2019-11-11	2022-07-29	因赛特公司	Pd-1/pd-l1抑制剂的盐及结晶形式
TW202233615A (zh)	2020-11-06	2022-09-01	美商英塞特公司	Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
CN116670114A (zh)	2020-11-06	2023-08-29	因赛特公司	用于制备pd-1/pd-l1抑制剂以及其盐和结晶形式的方法
WO2022099018A1 (en)	2020-11-06	2022-05-12	Incyte Corporation	Process of preparing a pd-1/pd-l1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4041624B2 (ja) *	1999-07-21	2008-01-30	三井化学株式会社	有機電界発光素子
US6489337B1 (en) *	2000-03-31	2002-12-03	Ortho-Mcneil Pharmaceutical, Inc.	Method for treating histamine H3 receptor-mediated disorders with 2- or 3-aryl substituted imidazo[1,2-a] pyridines
GB0119911D0 (en) *	2001-08-15	2001-10-10	Novartis Ag	Organic Compounds
MY133311A (en) *	2002-09-19	2007-11-30	Schering Corp	Novel imidazopyridines as cyclin dependent kinase inhibitors
GB0303503D0 (en) *	2003-02-14	2003-03-19	Novartis Ag	Organic compounds
US7432278B2 (en) *	2004-03-08	2008-10-07	The University Of North Carolina At Chapel Hill	Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents

2006
- 2006-09-22 FR FR0608350A patent/FR2906250B1/fr active Active
2007
- 2007-09-13 TW TW096134253A patent/TWI381837B/zh not_active IP Right Cessation
- 2007-09-19 CN CN2007800352403A patent/CN101516881B/zh not_active Expired - Fee Related
- 2007-09-19 ME MEP-2009-107A patent/ME00615B/me unknown
- 2007-09-19 AT AT07848251T patent/ATE467633T1/de active
- 2007-09-19 EP EP07848251A patent/EP2069342B1/fr active Active
- 2007-09-19 DK DK07848251.0T patent/DK2069342T3/da active
- 2007-09-19 CA CA2662848A patent/CA2662848C/fr not_active Expired - Fee Related
- 2007-09-19 ES ES07848251T patent/ES2345016T3/es active Active
- 2007-09-19 AU AU2007298856A patent/AU2007298856B2/en not_active Ceased
- 2007-09-19 UA UAA200903928A patent/UA95976C2/ru unknown
- 2007-09-19 PT PT07848251T patent/PT2069342E/pt unknown
- 2007-09-19 ZA ZA200901551A patent/ZA200901551B/xx unknown
- 2007-09-19 MX MX2009002802A patent/MX2009002802A/es active IP Right Grant
- 2007-09-19 EA EA200970311A patent/EA017442B1/ru not_active IP Right Cessation
- 2007-09-19 MY MYPI20091157A patent/MY145603A/en unknown
- 2007-09-19 RS RSP-2010/0356A patent/RS51412B/en unknown
- 2007-09-19 PL PL07848251T patent/PL2069342T3/pl unknown
- 2007-09-19 NZ NZ575337A patent/NZ575337A/en not_active IP Right Cessation
- 2007-09-19 JP JP2009528752A patent/JP5336378B2/ja not_active Expired - Fee Related
- 2007-09-19 BR BRPI0718517-0A patent/BRPI0718517A2/pt active Search and Examination
- 2007-09-19 AR ARP070104136A patent/AR062897A1/es not_active Application Discontinuation
- 2007-09-19 KR KR1020097005741A patent/KR101470039B1/ko not_active IP Right Cessation
- 2007-09-19 WO PCT/FR2007/001517 patent/WO2008034974A1/fr active Application Filing
- 2007-09-19 DE DE602007006525T patent/DE602007006525D1/de active Active
- 2007-09-19 SI SI200730316T patent/SI2069342T1/sl unknown
- 2007-09-20 JO JO2007401A patent/JO2643B1/en active
- 2007-09-20 PE PE2007001266A patent/PE20080671A1/es not_active Application Discontinuation
- 2007-09-21 UY UY30603A patent/UY30603A1/es not_active Application Discontinuation
- 2007-09-21 CL CL200702733A patent/CL2007002733A1/es unknown
2009
- 2009-02-26 CR CR10643A patent/CR10643A/es unknown
- 2009-03-02 IL IL197352A patent/IL197352A/en not_active IP Right Cessation
- 2009-03-05 GT GT200900049A patent/GT200900049A/es unknown
- 2009-03-10 TN TN2009000081A patent/TN2009000081A1/fr unknown
- 2009-03-18 HN HN2009000502A patent/HN2009000502A/es unknown
- 2009-03-19 US US12/407,449 patent/US7915284B2/en not_active Expired - Fee Related
- 2009-03-19 NI NI200900037A patent/NI200900037A/es unknown
- 2009-03-19 CO CO09028759A patent/CO6160308A2/es unknown
- 2009-03-19 SV SV2009003193A patent/SV2009003193A/es active IP Right Grant
- 2009-04-16 MA MA31788A patent/MA30792B1/fr unknown
- 2009-04-20 NO NO20091562A patent/NO20091562L/no not_active Application Discontinuation
2010
- 2010-02-22 HK HK10101842.6A patent/HK1135388A1/xx not_active IP Right Cessation
- 2010-07-20 CY CY20101100678T patent/CY1110232T1/el unknown
- 2010-07-23 HR HR20100408T patent/HRP20100408T1/hr unknown

Also Published As

Publication number	Publication date
EP2069342A1 (fr)	2009-06-17
FR2906250A1 (fr)	2008-03-28
RS51412B (en)	2011-02-28
UA95976C2 (en)	2011-09-26
FR2906250B1 (fr)	2008-10-31
KR20090054449A (ko)	2009-05-29
DE602007006525D1 (de)	2010-06-24
MA30792B1 (fr)	2009-10-01
PE20080671A1 (es)	2008-07-14
NI200900037A (es)	2014-02-20
US20090253735A1 (en)	2009-10-08
IL197352A (en)	2014-11-30
IL197352A0 (en)	2009-12-24
TN2009000081A1 (en)	2010-08-19
NZ575337A (en)	2011-12-22
PT2069342E (pt)	2010-07-19
BRPI0718517A2 (pt)	2013-11-19
JO2643B1 (en)	2012-06-17
TW200833329A (en)	2008-08-16
TWI381837B (zh)	2013-01-11
HN2009000502A (es)	2011-07-11
CR10643A (es)	2009-04-29
JP2010504309A (ja)	2010-02-12
HK1135388A1 (es)	2010-06-04
MY145603A (en)	2012-03-15
EA200970311A1 (ru)	2009-08-28
CL2007002733A1 (es)	2008-04-11
SV2009003193A (es)	2010-02-01
EA017442B1 (ru)	2012-12-28
MEP10709A (en)	2011-12-20
MX2009002802A (es)	2009-04-01
CY1110232T1 (el)	2015-01-14
SI2069342T1 (sl)	2010-09-30
AU2007298856B2 (en)	2012-08-09
JP5336378B2 (ja)	2013-11-06
NO20091562L (no)	2009-04-20
DK2069342T3 (da)	2010-08-23
EP2069342B1 (fr)	2010-05-12
CO6160308A2 (es)	2010-05-20
KR101470039B1 (ko)	2014-12-05
ATE467633T1 (de)	2010-05-15
PL2069342T3 (pl)	2010-10-29
AR062897A1 (es)	2008-12-10
CN101516881B (zh)	2012-07-18
ES2345016T3 (es)	2010-09-13
ME00615B (me)	2011-12-20
AU2007298856A1 (en)	2008-03-27
ZA200901551B (en)	2010-06-30
WO2008034974A1 (fr)	2008-03-27
US7915284B2 (en)	2011-03-29
GT200900049A (es)	2010-03-04
CN101516881A (zh)	2009-08-26
CA2662848A1 (fr)	2008-03-27
UY30603A1 (es)	2008-05-02
CA2662848C (fr)	2014-12-23

Publication	Publication Date	Title
HRP20100408T1 (hr)	2010-09-30	DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI
HRP20130029T1 (hr)	2013-02-28	POLISUPSTITUIRANI DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI
JP6782756B2 (ja)	2020-11-11	Ｋｉｔに関連する疾患を治療するために有用な化合物の製法と中間体化合物
JP5508385B2 (ja)	2014-05-28	多置換２−アリール−６−フェニル−イミダゾ［１，２−ａ］ピリジン誘導体、ならびにこれらの調製および治療的使用
Liverton et al.	1999	Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase
JP5738310B2 (ja)	2015-06-24	ジフェニル−ピラゾロピリジン誘導体、この誘導体の調製および調節因子ではなく核受容体としてのこの誘導体の使用
US10533011B2 (en)	2020-01-14	Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
JP2011515381A5 (es)	2012-03-08
Viswambharan et al.	2011	Synthesis and catalytic properties of 4-aryl-2, 3-dihydro-4 H-pyrimido [2, 3-b] benzothiazoles for asymmetric acyl or carboxyl group transfer reactions
AR051919A1 (es)	2007-02-21	Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto
NZ588084A (en)	2012-07-27	POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
HRP20110015T1 (hr)	2011-02-28	DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI
JP2021536471A (ja)	2021-12-27	メチル６−（２，４−ジクロロフェニル）−５−［４−［（３ｓ）−１−（３−フルオロプロピル）ピロリジン−３−イル］オキシフェニル］−８，９−ジヒドロ−７ｈ−ベンゾ［７］アンヌレン−２−カルボキシレートの塩およびその製造方法
NZ630467A (en)	2017-02-24	Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US7772248B2 (en)	2010-08-10	Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
JPWO2021155468A5 (es)	2024-02-07
Mesaros et al.	2012	Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo [2, 1-f][1, 2, 4] triazines: identification of orally bioavailable, efficacious ALK inhibitors
RU2010119560A (ru)	2011-11-27	Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение
ES2912264T3 (es)	2022-05-25	Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
HRP20151282T1 (hr)	2016-01-01	Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina
US20170037049A1 (en)	2017-02-09	Heteroaromatic compounds and their use as dopamine d1 ligands
HRP20141119T1 (hr)	2015-01-30	Derivati 5-fenilpirazolopiridina, njihovo dobivanje i njihova upotreba u terapiji
Zou et al.	2016	Asymmetric Construction of Functionalized 1, 2-Dihydropyridine and Pyridine Derivatives with Adjacent Stereocenters via a Unified Metal-Free Catalytic Approach
Bingi et al.	2014	A simple and catalyst free one pot access to the pyrazolone fused 2, 8-dioxabicyclo [3.3. 1] nonanes
RU2022101542A (ru)	2022-02-03	Сокристаллы бензоата лития и их применения